Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
URGN Transcript
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary indicates strong product development and market strategy, with ZUSDURI outperforming JELMYTO and expanding into community practices. Despite increased expenses and net loss, the optimistic guidance for ZUSDURI and strategic transition plans to UGN-103 suggest positive future prospects. The Q&A section reinforces confidence in ZUSDURI's growth, despite management's cautious responses. The absence of negative financial surprises and steady product adoption supports a positive sentiment, likely leading to a stock price increase of 2% to 8%.
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Financial performance shows increased expenses and losses, while product development highlights potential growth with new launches and trials. However, the Q&A reveals delays and uncertainties in revenue recognition and adoption, impacting short-term expectations. The lack of clear guidance on demand and revenue timelines, coupled with financial losses, outweighs the positive aspects, leading to a negative sentiment.
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
Unknown8-9
The earnings call summary presents a mixed picture. Financial performance is weak due to a widening net loss, but the company has a strong balance sheet. Product development is positive with ongoing trials and new acquisitions, yet market strategy faces hurdles like reimbursement issues. The Q&A highlights management's optimism but lacks concrete metrics, which may concern investors. The absence of short-term guidance adds uncertainty. Despite potential in new drugs, the immediate outlook is uncertain, balancing positive long-term prospects with short-term challenges, resulting in a neutral sentiment.
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerns: missed EPS expectations, significant net loss, increased expenses, and no shareholder return plan. Despite optimistic guidance and strategic initiatives, these financial challenges and potential regulatory risks overshadow the positives. The Q&A session did not alleviate concerns, with some unclear responses. Given these factors, the stock is likely to experience a negative reaction in the short term.
URGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
